NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP
Legend Biotech Corp. LEGN
8 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$1.0B
▲ 64.0% vs FY2024
EPS · FY25
$-0.81
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-28.5%
Net margin · FY25
-28.8%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 1.0B
Revenue, FY2025 · full 8-year series below
Revenue
Net income
The company lost 29 cents on every revenue dollar this year.
Per share
USD -0.81
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-28.5%
Return on equity, FY2025
ROE
Operating margin-13.3%
Net margin-28.8%
Return on assets-17.4%
Each USD of equity lost 29 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+68.8% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+106.4%
+68.8%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
—
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 1.7B
total assets, end of FY2025
Total assetsUSD 1.7B
CashUSD 901.9M
Gross debtUSD 319.1M
Net debtUSD -582.8M
Current ratio1.96×
History
8 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
Revenue $B
1.0
0.6
0.3
0.1
0.1
0.1
0.1
0.0
Operating income $B
−0.1
−0.3
−0.5
·
·
·
·
·
EBITDA $B
·
·
·
·
·
·
·
·
Income tax $B
0.0
0.0
−0.0
0.0
−0.0
−0.0
−0.0
0.0
Net income $B
−0.3
−0.2
−0.5
−0.4
−0.4
−0.3
−0.1
−0.0
EPS, diluted $
−0.81
−0.48
−1.47
−1.40
−1.43
−1.13
−0.51
−0.01
Dividend / sh $
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
ROE %
−28.5
−15.4
−51.9
−59.1
−59.2
−71.1
−67.1
·
Shares out B
·
·
·
·
·
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
22 of 22
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed